초록 ▼

The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleot

The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided.

대표청구항 ▼

1. A method of delivering multiple single stranded targeting oligonucleotides to a liver or kidney cell, the method comprising: contacting a liver or kidney cell with a compound under conditions in which the compound enters into the cell, wherein the compound comprises the general formula: X-L-[X-L]

1. A method of delivering multiple single stranded targeting oligonucleotides to a liver or kidney cell, the method comprising: contacting a liver or kidney cell with a compound under conditions in which the compound enters into the cell, wherein the compound comprises the general formula: X-L-[X-L]i-X,wherein i is an integer from 0 to 9, the value of which indicates the number of units of [X-L]i present in the compound,wherein each X is independently a single stranded targeting oligonucleotide of 8 to 16 nucleotides in length having a region of complementarity comprising at least 7 contiguous nucleotides complementary to a target region of a genomic target sequence, wherein adjacent nucleotides of the region of complementarity of each X comprise phosphorothioate linkages, and each L is an single stranded oligonucleotide linker consisting of 2 to 4 contiguous thymidine or uridine nucleotide residues linked through phosphodiester linkages, that links at least two Xs and that is more susceptible to cleavage in a mammalian liver or kidney cell extract than each X,wherein when i=0, and the general formula is 5′X3′-L-5′X3′ and when the target regions complementary to the first X and second X do not overlap in the genomic target sequence, the 5′-end of the target region complementary to the first X and the 3′-end of the target region complementary to the second X are not within a distance of 0 to 4 nucleotides in the genomic target sequence,wherein at least one L does not comprise an oligonucleotide having a self-complementary nucleotide sequence, andwherein at least one L does not comprise an oligonucleotide having a nucleotide sequence that is complementary to a region of the genomic target sequence that is contiguous with the target regions complementary to two immediately flanking Xs. 2. The method of claim 1, wherein i is an integer from 1 to 9. 3. The method of claim 1, wherein each L consists of 3 or 4 contiguous thymidine or uridine nucleotide residues linked through phosphodiester linkages. 4. The method of claim 1, wherein the linker is cleaved after the compound enters the cell. 5. The method of claim 1, wherein i is 0. 6. The method of claim 1, wherein each X of the compound has a different region of complementarity than each other X of the compound, such that the Xs of the compound target different genomic target sequences. 7. The method of claim 1, wherein each X is independently complementary to an mRNA or a long non-coding RNA. 8. The method of claim 5, wherein L consists of 3 or 4 contiguous thymidine or uridine nucleotide residues linked through phosphodiester linkages. 9. The method of claim 3, wherein each L consists of 3 or 4 contiguous thymidine nucleotide residues linked through phosphodiester linkages. 10. The method of claim 3, wherein each L consists of 4 contiguous thymidine nucleotide residues linked through phosphodiester linkages. 11. The method of claim 3, wherein each L consists of 3 or 4 contiguous uridine nucleotide residues linked through phosphodiester linkages. 12. The method of claim 3, wherein each L consists of 4 contiguous uridine nucleotide residues linked through phosphodiester linkages. 13. The method of claim 8, wherein L consists of 3 or 4 contiguous thymidine nucleotide residues linked through phosphodiester linkages. 14. The method of claim 8, wherein L consists of 4 contiguous thymidine nucleotide residues linked through phosphodiester linkages. 15. The method of claim 8, wherein L consists of 3 or 4 contiguous uridine nucleotide residues linked through phosphodiester linkages. 16. The method of claim 8, wherein L consists of 4 contiguous uridine nucleotide residues linked through phosphodiester linkages. 17. The method of claim 1, wherein the cell is a liver cell. 18. The method of claim 5, wherein the cell is a liver cell.